Jeon Hwa-seong's Startup Morning Coffee, Episode 1093: PhyCell's Innovation and Growth Strategy

Every morning, the YouTube program 'Startup Morning Coffee,' which conveys the vibrant energy of the startup ecosystem, comes to viewers. As the flagship program of the 'Jeon Hwa-sung's CNTV' channel, led by CEO Jeon Hwa-sung, it deeply illuminates the core competencies and market potential of promising startups through live broadcasts every day at 8:40 AM. As an interactive platform that goes beyond simple information delivery through real-time comment communication, it plays an indispensable guiding role for those interested in startups. In this broadcast, 'PICELL,' an innovative company aiming for advanced regenerative medicine total solutions, was introduced, drawing significant attention. PICELL is demonstrating an unrivaled presence in the field of natural killer cell (NK Cell) culture technology, which is essential for cancer prevention and treatment. In particular, it is attracting attention from the industry by developing innovative technology that utilizes its proprietary patented substance 'PNK1' to increase NK cell proliferation efficiency by more than 10 times compared to general culture media. Their technology encompasses high-purity NK cell and stem cell culture, holding the potential to lead Korea's 50 billion KRW regenerative medicine market. Currently, PICELL is solidifying its foundation for growth through CNTTech's Kibo Venture Camp support program. Based on this high-efficiency NK cell culture technology, PICELL is envisioning diverse business models, including advanced regenerative medicine service consulting, cell culture media sales, and cell CDM (Contract Development and Manufacturing) businesses. To secure a stable revenue structure, strategies for cell supply and media sales through the establishment of its own production facilities are also being concretized. CEO Jeon Hwa-sung expressed high expectations, stating that PICELL's innovative NK cell and stem cell culture technology will play a pivotal role in the advanced regenerative medicine market. He emphasized that, given PICELL's grand business model and growth targets, it will establish itself as a leading company that opens new horizons in the fields of cancer treatment and regenerative medicine, giving significant credit to its growth potential.